Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 783 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bioequivalence Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

NCT06440980
View directory record Official record
Conditions
Healthy, Obese, Overweight, Obesity
Interventions
Orforglipron
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
533 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
7
States / cities
Anaheim, California • Los Alamitos, California • Daytona Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult Participants

NCT05767398
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Zanubrutinib
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Mycophenolate Mofetil 250 mg Capsules Under Fed Conditions

NCT00910663
View directory record Official record
Conditions
Healthy
Interventions
Mycophenolate Mofetil, CellCept®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects

NCT02823171
View directory record Official record
Conditions
Healthy
Interventions
Treatment A: 400 mg Pacritinib P3CT, Treatment B: 400 mg of pacritinib FMI
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fasting Conditions

NCT00829764
View directory record Official record
Conditions
Healthy
Interventions
Doxycycline Monohydrate
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Amoxicillin 400 mg/Clavulanic Acid 57 mg Chewable Tablets Under Fed Conditions

NCT00778284
View directory record Official record
Conditions
Healthy
Interventions
Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 23, 2008 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects

NCT03517943
View directory record Official record
Conditions
Clinical Pharmacology
Interventions
Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG), Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Non-fasting Conditions

NCT00865384
View directory record Official record
Conditions
Healthy
Interventions
Mirtazapine 15 mg tablets, single dose, REMERON® 15 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Propranolol HCl 160 mg Tablets Under Non-fasting Conditions

NCT00864747
View directory record Official record
Conditions
Healthy
Interventions
Propranolol Hydrochloride Extended Release Capsules 160 mg, INDERAL® LA 160 mg Capsules, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 21, 2026, 10:32 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants

NCT07610005
View directory record Official record
Conditions
Healthy
Interventions
Varegacestat Reference Formulation, Varegacestat Test Formulation
Drug
Lead sponsor
Immunome, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug Interaction With Proton Pump Inhibitors for Nifedipine ER Tablets

NCT03100838
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Nifedipine 60 MG Extended Release Oral Tablet, omeprazole/sodium bicarbonate, SmartPill (TM)
Drug · Device
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 16, 2019 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sensitivity of Pharmacokinetics to Differences in Particle Size Distribution of Suspension-based Nasal Sprays

NCT02588326
View directory record Official record
Conditions
Hypersensitivity
Interventions
Mometasone furoate drug formulation (MFF) 1, Mometasone furoate drug formulation (MFF) 2
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 21, 2026, 10:32 PM EDT
Not listed Phase 1 Interventional

A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer

NCT01715168
View directory record Official record
Conditions
Ovarian Cancer, Malignant Female Reproductive System Neoplasm, Cancer, Ovarian Tumor, Ovarian Epithelial Cancer Recurrent
Interventions
DOXIL/CAELYX, ATI-0918
Drug
Lead sponsor
Azaya Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Yakima, Washington
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Delayed-Release Tablets 20 mg

NCT00648349
View directory record Official record
Conditions
Healthy
Interventions
Rabeprazole Sodium Delayed-Release Tablets 20 mg, Aciphex® Delayed-Release Tablets 20 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Bioequivalency Study of Montelukast 10 mg Tablets Under Fed Conditions

NCT01659918
View directory record Official record
Conditions
Asthma
Interventions
Montelukast, Singulair
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg

NCT00648063
View directory record Official record
Conditions
Healthy
Interventions
Letrozole Tablets 2.5 mg, Femara® Tablets 2.5 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
40 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Azithromycin Tablets 600 mg to Zithromax® Tablets 600 mg

NCT00649935
View directory record Official record
Conditions
Healthy
Interventions
Azithromycin Tablets 600 mg, Zithromax® Tablets 600 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized, Crossover Bioequivalence Study of PL-ASA Versus Immediate Release Aspirin in Healthy Volunteers.

NCT05055752
View directory record Official record
Conditions
Bioequivalence
Interventions
Pharmaceutical-lipid aspirin (PL-ASA)
Drug
Lead sponsor
PLx Pharma
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

90 mg Fluoxetine Hydrochloride Capsules Under Non-Fasting Conditions

NCT01247285
View directory record Official record
Conditions
Healthy
Interventions
Fluoxetine Hydrochloride, PROZAC WEEKLY®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2011 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pantoprazole Sodium 40 mg DR Tablets Under Non-Fasting Conditions

NCT00835393
View directory record Official record
Conditions
Healthy
Interventions
Pantoprazole Sodium 40 mg delayed-release tablets, PROTONIX® 40 mg delayed-release tablets.
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
2
States / cities
Saint Charles, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2009 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Levetiracetam 1000 mg Under Fasting Conditions

NCT00859521
View directory record Official record
Conditions
Healthy
Interventions
Levetiracetam, Keppra®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 21, 2026, 10:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Ciprofloxacin Extended-Release Tablets 500 mg and Cipro® XR Tablets 500 mg

NCT00649155
View directory record Official record
Conditions
Healthy
Interventions
Ciprofloxacin Extended-Release Tablets 500 mg, Cipro® XR Tablets (500 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 21, 2026, 10:32 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Lispro (Listro™) With Humalog® in Healthy Subjects

NCT01399255
View directory record Official record
Conditions
Bioequivalence in Healthy Subjects
Interventions
Insulin lispro
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 21, 2026, 10:32 PM EDT
Terminated Phase 3 Interventional

WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant Recipients

NCT00275314
View directory record Official record
Conditions
Kidney Transplant
Interventions
Valganciclovir
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 68 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Oct 21, 2026, 10:32 PM EDT